Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 9, 2014, Pages 1251-1258

  Shrestha, Ayush ^a   Krishnamurthy, Praveen T ^a   Thomas, Pooja ^a   Hammock, Bruce D ^b   Hwang, Sung H ^b  

^a JSS COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ischaemic injury; isoproterenol (ISO); soluble epoxide hydrolase inhibitor; t TUCB

Indexed keywords

ANTIOXIDANT; CALCIUM; CARDIOVASCULAR AGENT; CATALASE; CREATINE KINASE MB; HYDROLASE INHIBITOR; ISOPRENALINE; LACTATE DEHYDROGENASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; SUPEROXIDE DISMUTASE; TRANS 4 [4 [3 (4 TRIFLUOROMETHOXYPHENYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; UNCLASSIFIED DRUG; 4-(4-(3-(4-TRIFLUOROMETHOXY-PHENYL)UREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; CARDIOTONIC AGENT; EPOXIDE HYDROLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATINE KINASE MB BLOOD LEVEL; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART WEIGHT; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; Q WAVE; QT PROLONGATION; RAT; ST SEGMENT DEPRESSION; T WAVE INVERSION; TISSUE LEVEL; TREATMENT DURATION; WISTAR RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HEART; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; MYOCARDIAL INFARCTION; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; ANTIOXIDANTS; BENZOATES; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; EPOXIDE HYDROLASES; HEART; HEART CONDUCTION SYSTEM; ISOPROTERENOL; LIPID PEROXIDATION; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; RATS, WISTAR; REPERFUSION INJURY;

EID: 84906319176     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12251     Document Type: Article

References (32)

1. Gaziano T, et al. Cardiovascular disease. In:, Jamison DT, et al., eds. Disease Control Priorities in Developing Countries, 2nd edn. New York: Oxford University Press, 2006: 649-650.
2. Toldo S, et al. Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse. J Am Heart Assoc 2012; 5: e002360.
3. Penna C, et al. Cardioprotection: a radical view. Free radicals in pre and postconditioning. Biochim Biophys Acta 2009; 7: 781-793.
4. Hoffman JW Jr, et al. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 2004; 4: 391-411.
5. Xu X, et al. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 2011; 8: 597-609.
6. Nithipatikom K, Gross GJ,. Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 2010; 2: 112-119.
7. Gross GJ, et al. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 2007; 3: 687-691.
8. Lu T, et al. Stereospecific activation of cardiac ATP-sensitive K(+) channels by epoxyeicosatrienoic acids: a structural determinant study. Mol Pharmacol 2002; 5: 1076-1083.
9. Lu T, et al. Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 2001; 537 (Pt. 3): 811-827.
10. Theroux P,. Protection of the myocardial cell during ischemia. Am J Cardiol 1999; 10A: 3G-9G.
11. Gross GJ, Auchampach JA,. Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res 1992; 11: 1011-1016.
12. Liu L, et al. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 2011; 2: 451-463.
13. Zhao G, et al. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J Lipid Res 2012; 3: 456-466.
14. Yan G, et al. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res 2008; 2: 308-314.
15. Fleming I,. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007; 1-4: 60-67.
16. Spector AA, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004; 1: 55-90.
17. Shen HC,. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat 2010; 7: 941-956.
18. Anandan SK, et al. Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 2009; 4: 1066-1070.
19. Hwang SH, et al. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007; 16: 3825-3840.
20. Kim IH, et al. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 2004; 8: 2110-2122.
21. Watanabe T, et al. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos 2003; 7: 846-853.
22. Wagner K, et al. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models. Eur J Pharmacol 2013; 1-3: 93-101.
23. Liu JY, et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 2009; 2: 284-296.
24. Ohkawa H, et al. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 2: 351-358.
25. Beers RF Jr, Sizer IW,. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952; 1: 133-140.
26. Saggu H, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989; 3: 692-697.
27. Liu JY, et al. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. Eur J Pharm Sci 2013; 4-5: 619-627.
28. Guedes AG, et al. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. Vet Anaesth Analg 2013; 4: 440-448.
29. Yogeeta SK, et al. Synergistic interactions of ferulic acid with ascorbic acid: its cardioprotective role during isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 2006; 1-2: 139-146.
30. Khatua TN, et al. Garlic provides protection to mice heart against isoproterenol-induced oxidative damage: role of nitric oxide. Nitric Oxide 2012; 1: 9-17.
31. Gupta P, et al. Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implication. J Transl Med 2013; 11: 1-6.
32. Batchu SN, et al. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 1: 67-74.